SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Evans Thomas George

(Last) (First) (Middle)
C/O VACCITECH PLC, THE SCHRODINGER BLDG
HEATLEY ROAD,THE OXFORD SCIENCE PARK

(Street)
OXFORD X0 0X4 4GE

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/29/2021
3. Issuer Name and Ticker or Trading Symbol
Vaccitech plc [ VACC ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1) 127,926 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (Right to Buy) (2) 02/16/2028 Ordinary Shares(1) 15,450 $0.0004(2) D
Share Option (Right to Buy) (3) 08/14/2029 Ordinary Shares(1) 12,360 $0.0004(3) D
Share Option (Right to Buy) (4) 01/08/2030 Ordinary Shares(1) 12,360 $0.0004(4) D
Share Option (Right to Buy) (5) 06/23/2030 Ordinary Shares(1) 255,852 $0.0001(5) D
Share Option (Right to Buy) (6) 02/12/2031 Ordinary Shares(1) 30,900 $0.0001(6) D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. This option shall vest and become exercisable in four equal annual installments, with the first installment vested on February 1, 2019. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019.
3. This option shall vest and become exercisable in four equal annual installments, with the first installment vested on February 1, 2020. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019.
4. This option shall vest and become exercisable in four equal annual installments, with the first installment vested on January 1, 2021. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3662 to GBP 1.00 on December 31, 2020.
5. This option shall vest and become exercisable in three equal annual installments, with the first installment vested on October 10, 2019. The exercise price of this option is GBP 0.000032 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3662 to GBP 1.00 on December 31, 2020.
6. This option shall vest and become exercisable in four equal annual installments, with the first installment vesting on February 1, 2022. The exercise price of this option is GBP 0.000032 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3662 to GBP 1.00 on December 31, 2020.
Remarks:
Exhibit 24 - Power of Attorney
/s/ William Enright, Attorney-in-Fact 04/29/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.